<DOC>
	<DOCNO>NCT00374647</DOCNO>
	<brief_summary>Evaluate safety efficacy early corticosteroid withdrawal simultaneous calcineurin inhibitor withdrawal recipient primary renal allograft maintain long-term MMF sirolimus .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Early Calcineurin Inhibitor Withdrawal Primary Renal Allografts</brief_title>
	<detailed_description />
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Male female patient 18 75 year age . Patients 90 240 day receive primary living cadaver renal allograft . Patients maintain regimen cyclosporine tacrolimus MMF since transplantation . Capable provide write informed consent . No known contraindication treatment sirolimus . Pregnant lactating . Acute rejection within 90 day prior study randomization . More one biopsy proven acute rejection episode prior study randomization . Previously receive receive organ transplant kidney . Receiving sirolimus prior entry . Severe diarrhea gastrointestinal disorder may interfere ability absorb oral medication . Evidence active systemic infection require antibiotic , HIV , HCV , HBV infection . History malignancy past 5 year . Require dialysis time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Renal</keyword>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
</DOC>